PDF Version

PDF版本

DURHAM, N.C., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, today announced that it entered into a securities purchase agreement with an institutional investor to purchase approximately $30.0 million worth of its common stock and warrants in a registered direct offering..

北卡罗来纳州达勒姆，2024年10月4日（环球通讯社）--Humacyte，Inc.（纳斯达克：HUMA），一家临床阶段生物技术平台公司，以商业规模开发普遍植入式生物工程人体组织，今天宣布，它与一家机构投资者签订了证券购买协议，以注册直接发行的方式购买价值约3000万美元的普通股和认股权证。。

Under the terms of the securities purchase agreement, the Company has agreed to sell 5,681,820 shares of its common stock and warrants to purchase 5,681,820 shares of common stock. 2,840,910 warrants will be exercisable immediately, have an exercise price of $5.28 per share, and will expire six months from the initial exercise date.

根据证券购买协议的条款，公司已同意出售5681820股普通股和认购5681820股普通股的认股权证。2840910份认股权证将立即行权，行权价格为每股5.28美元，自初始行权日起六个月到期。

The additional 2,840,910 warrants will be exercisable immediately, have an exercise price of $5.28 per share, and will expire four and a half years from the initial exercise date. The purchase price for one share of common stock and one warrant will be $5.28..

额外的2840910份认股权证将立即行权，行权价格为每股5.28美元，自首次行权日起四年半到期。一股普通股和一份认股权证的购买价格为5.28美元。。

The gross proceeds to the Company from the registered direct offering are estimated to be approximately $30.0 million, before deducting the placement agent’s fees and other estimated offering expenses. The offering is expected to close on or about October 7, 2024, subject to the satisfaction of customary closing conditions..

在扣除配售代理费和其他预计的发行费用之前，注册直接发行给公司的总收益估计约为3000万美元。预计本次发行将于2024年10月7日左右结束，但须符合惯例的结束条件。。

EF Hutton LLC is acting as exclusive placement agent for the offering.

。

The proposed offering of the common stock and warrants described above is being offered by the Company pursuant to a “shelf” registration statement on Form S-3 (File No. 333-267225) filed with the Securities and Exchange Commission (SEC) and declared effective by the SEC on September 9, 2022, and the accompanying prospectus contained therein..

上述普通股和认股权证的拟议发售由本公司根据S-3表格（文件号333-267225）上的“货架”登记声明进行发售，该登记声明已向美国证券交易委员会（SEC）提交，并于2022年9月9日由SEC宣布生效，以及其中包含的随附招股说明书。。

The offering is being made only by means of a prospectus supplement and accompanying prospectus. A prospectus supplement describing the terms of the public offering will be filed with the SEC and will form a part of the effective registration statement.

本次发行仅通过补充招股说明书和随附招股说明书进行。描述公开发行条款的补充招股说明书将提交给SEC，并将构成有效登记声明的一部分。

Copies of the prospectus supplement and the accompanying prospectus relating to this offering may be obtained, when available, on the SEC’s website at http://www.sec.gov or by contacting EF Hutton LLC Attention: Syndicate Department, 590 Madison Avenue, 39th Floor, New York, NY 10022, by email at syndicate@efhutton.com, or by telephone at (212) 404-7002..

有关本次发行的补充招股说明书和随附招股说明书的副本，可在美国证券交易委员会的网站上获得http://www.sec.gov或联系EF Hutton LLC收件人：Syndicate Department，590 Madison Avenue，39th Floor，New York，NY 10022，电子邮件地址：syndicate@efhutton.com，或致电（212）404-7002。。

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction..

本新闻稿不构成出售要约或招揽购买本新闻稿所述任何证券的要约，也不构成在任何州或司法管辖区的证券法律规定登记或取得资格之前，在任何州或司法管辖区出售这些证券都是非法的。。

About Humacyte

关于腐殖酸盐

Humacyte, Inc. (Nasdaq: HUMA) is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues, advanced tissue constructs, and organ systems designed to improve the lives of patients and transform the practice of medicine. The Company develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions.

Humacyte，Inc.（纳斯达克股票代码：HUMA）正在开发一个颠覆性的生物技术平台，以提供普遍植入的生物工程人体组织，先进的组织构建体和器官系统，旨在改善患者的生活并改变医学实践。该公司开发和制造无细胞组织，用于治疗各种疾病、伤害和慢性病。

Humacyte’s initial product candidates, a portfolio of ATEVs, are currently in late-stage clinical trials targeting multiple vascular applications, including vascular trauma repair, arteriovenous (AV) access for hemodialysis, and peripheral artery disease. A Biologics License Application for the ATEV in the vascular trauma indication is currently under review by the FDA and was granted Priority Review.

Humacyte最初的候选产品是一系列ATEV，目前正在进行针对多种血管应用的晚期临床试验，包括血管创伤修复，血液透析的动静脉（AV）通路和外周动脉疾病。目前，FDA正在审查ATEV在血管创伤适应症中的生物制剂许可证申请，并获得优先审查。

Preclinical development is also underway in coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple novel cell and tissue applications. Humacyte’s 6mm ATEV for AV access in hemodialysis was the first product candidate to receive the FDA’s Regenerative Medicine Advanced Therapy (RMAT) designation and has also received FDA Fast Track designation.

冠状动脉旁路移植术，儿科心脏手术，1型糖尿病治疗以及多种新型细胞和组织应用的临床前开发也在进行中。Humacyte用于血液透析AV通路的6mm ATEV是第一个获得FDA再生医学高级治疗（RMAT）指定的候选产品，并且还获得了FDA快速通道指定。

Humacyte’s 6mm ATEV for urgent arterial repair following extremity vascular trauma and for advanced PAD also have received an RMAT designations. The ATEV received priority designation for the treatment of vascular trauma by the U.S. Secretary of Defense. The ATEV is an investigational product and has not been approved for sale by the Food and Drug Administration or any international regulatory agency.

Humacyte的6mm ATEV用于肢体血管创伤后的紧急动脉修复和高级PAD也已获得RMAT指定。ATEV被美国国防部长优先指定用于治疗血管创伤。ATEV是一种研究产品，尚未获得食品和药物管理局或任何国际监管机构的批准销售。

For more information, visit www.Humacyte.com..

有关更多信息，请访问www.Humacyte.com。。

Forward-Looking Statements

前瞻性声明

This press release contains forward-looking statements that are based on beliefs and assumptions and on information currently available. In some cases, you can identify forward-looking statements by the following words: “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words.

本新闻稿包含基于信念和假设以及当前可用信息的前瞻性声明。在某些情况下，您可以通过以下词语来识别前瞻性陈述：“可能”，“将”，“可能”，“将”，“应该”，“期望”，“打算”，“计划”，“预期”，“相信”，“估计”，“预测”，“项目”，“潜在”，“继续”，“正在进行”或这些术语或其他类似术语的否定词，尽管并非所有前瞻性陈述都包含这些词语。

These statements involve risks, uncertainties, and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, we caution you that these statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain.

这些声明涉及风险、不确定性和其他因素，这些因素可能导致实际结果、活动水平、绩效或成就与这些前瞻性声明所表达或暗示的信息存在重大差异。虽然我们相信本新闻稿中的每一项前瞻性声明都有合理的依据，但我们提醒您，这些声明是基于我们目前已知的事实和因素以及我们对未来的预测，对此我们无法确定。

Forward-looking statements in this press release include, but are not limited to, the statements regarding the initiation, timing, progress, and results of our preclinical and clinical trials, including our BVP program; the anticipated characteristics and performance of our ATEV and the BVP; our ability to successfully complete preclinical and clinical trials for our ATEVs and the BVP; the anticipated benefits of the BVP relative to existing alternatives; the anticipated commercialization of our ATEVs and our ability to manufacture at commercial scale; the implementation of our business model and strategic plans for our business; and the timing or likelihood of regulatory filings, acceptances, and approvals.

本新闻稿中的前瞻性声明包括但不限于关于我们的临床前和临床试验（包括我们的BVP计划）的开始，时间，进展和结果的声明；我们的ATEV和BVP的预期特征和性能；我们成功完成ATEV和BVP的临床前和临床试验的能力；BVP相对于现有替代方案的预期收益；；我们业务模式和战略计划的实施；以及监管备案、接受和批准的时间或可能性。

We cannot assure you .

我们不能向你保证。

Humacyte Investor Contact:Joyce AllaireLifeSci Advisors LLC+1-617-435-6602jallaire@lifesciadvisors.cominvestors@humacyte.com

Humacyte投资者联系人：Joyce AllaireLifeSci Advisors LLC+1-617-435-6602jallaire@lifesciadvisors.cominvestors@humacyte.com

Humacyte Media Contact:Rich LuchettePrecision Strategies+1-202-845-3924rich@precisionstrategies.commedia@humacyte.com

Humacyte媒体接触：Rich-LuchettePrecision策略+1-202-845-3924rich@precisionstrategies.commedia@humacyte.com

Source: Humacyte, Inc

资料来源：Humacyte，Inc